1. Home
  2. ENTX vs SKYE Comparison

ENTX vs SKYE Comparison

Compare ENTX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • SKYE
  • Stock Information
  • Founded
  • ENTX 2010
  • SKYE 2012
  • Country
  • ENTX Israel
  • SKYE United States
  • Employees
  • ENTX N/A
  • SKYE N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENTX Health Care
  • SKYE Health Care
  • Exchange
  • ENTX Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • ENTX 90.2M
  • SKYE 80.7M
  • IPO Year
  • ENTX 2018
  • SKYE N/A
  • Fundamental
  • Price
  • ENTX $2.43
  • SKYE $3.16
  • Analyst Decision
  • ENTX Strong Buy
  • SKYE Buy
  • Analyst Count
  • ENTX 1
  • SKYE 6
  • Target Price
  • ENTX $10.00
  • SKYE $18.67
  • AVG Volume (30 Days)
  • ENTX 83.2K
  • SKYE 214.0K
  • Earning Date
  • ENTX 03-07-2025
  • SKYE 02-25-2025
  • Dividend Yield
  • ENTX N/A
  • SKYE N/A
  • EPS Growth
  • ENTX N/A
  • SKYE N/A
  • EPS
  • ENTX N/A
  • SKYE N/A
  • Revenue
  • ENTX $99,000.00
  • SKYE N/A
  • Revenue This Year
  • ENTX N/A
  • SKYE N/A
  • Revenue Next Year
  • ENTX N/A
  • SKYE N/A
  • P/E Ratio
  • ENTX N/A
  • SKYE N/A
  • Revenue Growth
  • ENTX 607.14
  • SKYE N/A
  • 52 Week Low
  • ENTX $0.95
  • SKYE $2.31
  • 52 Week High
  • ENTX $3.35
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 54.06
  • SKYE 52.61
  • Support Level
  • ENTX $2.21
  • SKYE $2.60
  • Resistance Level
  • ENTX $2.62
  • SKYE $3.54
  • Average True Range (ATR)
  • ENTX 0.21
  • SKYE 0.48
  • MACD
  • ENTX -0.01
  • SKYE 0.03
  • Stochastic Oscillator
  • ENTX 69.35
  • SKYE 34.73

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: